1272974-23-8

Basic information

• Product Name: carbonic acid pentafluorophenyl ester 3-trifluoromethyl-oxetan-3-yl ester
• Synonyms: carbonic acid pentafluorophenyl ester 3-trifluoromethyl-oxetan-3-yl ester
• CAS NO: 1272974-23-8
• Molecular Weight: 352.138
• Mol File: 1272974-23-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: carbonic acid pentafluorophenyl ester 3-trifluoromethyl-oxetan-3-yl ester(CAS DataBase Reference)
• NIST Chemistry Reference: carbonic acid pentafluorophenyl ester 3-trifluoromethyl-oxetan-3-yl ester(1272974-23-8)
• EPA Substance Registry System: carbonic acid pentafluorophenyl ester 3-trifluoromethyl-oxetan-3-yl ester(1272974-23-8)

Safety Data

• Hazardous Substances Data: 1272974-23-8(Hazardous Substances Data)

Upstream product

• 59483-84-0 bis(pentafluorophenyl)carbonate 
• 1403676-72-1 3-(trifluoromethyl)oxetan-3-ol 
• 6704-31-0 oxetan-3-one 
• 81290-20-2 (trifluoromethyl)trimethylsilane 

Downstream Products

• 1272973-54-2 3-(trifluoromethyl)oxetan-3-yl (3R)-4-[5-({2-fluoro-4-[(methylsulfonyl)methyl]benzyl}oxy)pyrimidin-2-yl]-3-methylpiperazine-1-carboxylate 
• 1272973-55-3 (R)-3-(trifluoromethyl)oxetan-3-yl 4-(5-(2-fluoro-4-(methylsulfonyl)benzyloxy)pyrimidin-2-yl)-3-methylpiperazine-1-carboxylate 
• 1415818-11-9 3-(trifluoromethyl)oxetan-3-yl 4-((1r,4r)-{4-[(3-cyanopyridin-4-yl)oxy]cyclohexyl}oxy)piperidine-1-carboxylate 

Relevant articles and documents

MODULATORS OF GPR119 AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and hydrates thereof, Formula (I), that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agen

Optimisation of aqueous solubility in a series of G protein coupled receptor 119 (GPR119) agonists

Improving aqueous solubility is a challenge frequently faced within drug discovery programs. Herein we describe increases in solubility in two sub-series of GPR119 agonists through reduction of lipophilicity together with hydrogen bond acceptor modulation

MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof, that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, an inhibitor of DPP-IV, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.